ReviewAdvances in experimental medicine and biology2026
Sialidase Activity Imaging of Different Organs with BTP3-Neu5Ac.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter offers an overview of the development of BTP3-Neu5Ac and the functions of sialidase, as revealed through its use. Imaging of sialidase activity in the brain with BTP3-Neu5Ac has demonstrated that high sialidase activity is primarily detected in the white matter. In the hippocampus, a region critical for memory, glutamatergic nerve terminals exhibit particularly high sialidase activity. Based on the sialidase activity atlas, it was found that sialidase plays a crucial role in cognitive function within the hippocampus. Real-time imaging of changes in brain sialidase activity using BTP3-Neu5Ac has shown that sialidase activity at nerve terminals can rapidly increase within seconds in response to neural activity. This rapid fluctuation in sialidase activity contributes to a negative feedback mechanism on excitatory neurotransmission by sialidase. Additionally, studies on the distribution of sialidase activity in the pancreas have shown that the sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA) promotes insulin secretion. Importantly, DANA does not induce insulin secretion during hypoglycemia, suggesting its potential for diabetes treatment with a lower risk of hypoglycemic side effects. Moreover, research into the distribution of sialidase activity in the skin has revealed that the sialidase isozyme NEU2 promotes elastin production. Thus, information on the distribution of sialidase activity in tissues provides valuable insights into the function of sialidase and supports the development of sialidase-targeted drugs.
Indexed as
Identifiers
41917401What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.